Bio-Rad Laboratories, Inc. (NYSE:BIO) is scheduled to release its earnings data after the market closes on Thursday, August 3rd. Analysts expect Bio-Rad Laboratories to post earnings of $0.49 per share for the quarter.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, May 4th. The medical research company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.14. Bio-Rad Laboratories had a net margin of 1.35% and a return on equity of 3.23%. The company had revenue of $500.05 million for the quarter, compared to analyst estimates of $477.76 million. During the same quarter in the previous year, the firm posted $0.42 earnings per share. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. On average, analysts expect Bio-Rad Laboratories to post $2.94 EPS for the current fiscal year and $4.58 EPS for the next fiscal year.

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) opened at 238.95 on Thursday. The stock has a 50 day moving average of $227.42 and a 200 day moving average of $209.13. Bio-Rad Laboratories, Inc. has a 52-week low of $143.26 and a 52-week high of $239.91. The company has a market cap of $5.85 billion, a price-to-earnings ratio of 254.20 and a beta of 0.91.

A number of equities analysts recently issued reports on BIO shares. Zacks Investment Research raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $244.00 price objective on the stock in a report on Monday, May 1st. Jefferies Group LLC reissued a “buy” rating and issued a $250.00 price objective on shares of Bio-Rad Laboratories in a report on Thursday, April 27th. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price objective on the stock. Deutsche Bank AG raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and dropped their price objective for the stock from $220.00 to $195.00 in a report on Wednesday, June 28th. Finally, BidaskClub raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $228.80.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Earnings History for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with's FREE daily email newsletter.